

Nihar R Desai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8322460/publications.pdf>

Version: 2024-02-01

209
papers

5,057
citations

147801

31
h-index

123424

61
g-index

213
all docs

213
docs citations

213
times ranked

7781
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of vitamins, minerals, and lead with lipoprotein(a) in a cross-sectional cohort of US adults. <i>International Journal for Vitamin and Nutrition Research</i> , 2023, 93, 99-110.	1.5	1
2	Outcomes of mechanical circulatory support for acute myocardial infarction complicated by cardiogenic shock. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 658-663.	1.7	17
3	Policy and Payment Challenges in the Postpandemic Treatment of Heart Failure: Value-Based Care and Telehealth. <i>Journal of Cardiac Failure</i> , 2022, 28, 835-844.	1.7	1
4	Trends in Heart Failure Hospitalizations in the US from 2008 to 2018. <i>Journal of Cardiac Failure</i> , 2022, 28, 171-180.	1.7	40
5	Trends in transcatheter and surgical aortic valve replacement in the United States, 2008-2018. <i>American Heart Journal</i> , 2022, 243, 87-91.	2.7	13
6	Rationale and design of a cluster-randomized pragmatic trial aimed at improving use of guideline directed medical therapy in outpatients with heart failure: PRagmatic trial of messaging to providers about treatment of heart failure (PROMPT-HF). <i>American Heart Journal</i> , 2022, 244, 107-115.	2.7	12
7	<scp>Costâ€effectiveness</scp> of <scp>secondâ€line</scp> empagliflozin versus liraglutide for type 2 diabetes in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 652-661.	4.4	9
8	Achievement and quality measure attainment in patients hospitalized with atrial fibrillation: Results from The Get With The Guidelines â€“ Atrial Fibrillation (GWTC-AFIB) registry. <i>American Heart Journal</i> , 2022, 245, 90-99.	2.7	2
9	Increased Dropout Rates in Model Year 4 of the Bundled Payments for Care Improvement Advanced Model. <i>Journal of General Internal Medicine</i> , 2022, , .	2.6	0
10	Comfort Measures Only in Myocardial Infarction: Prevalence of This Status, Change Over Time, and Predictors From a Nationwide Study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, e007610.	2.2	0
11	Hospital Characteristics and Early Enrollment Trends in the American College of Cardiology Voluntary Public Reporting Program. <i>JAMA Network Open</i> , 2022, 5, e2147903.	5.9	0
12	Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit. <i>Clinical Therapeutics</i> , 2022, 44, 52-66.e2.	2.5	6
13	Preexisting frailty and outcomes in older patients with acute myocardial infarction. <i>American Heart Journal</i> , 2022, 249, 34-44.	2.7	4
14	Reimagining Evidence Generation for Heart Failure and the Role of Integrated Health Care Systems. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, CIRCOUTCOMES121008292.	2.2	8
15	Patterns of care for first-detected atrial fibrillation: Insights from the Get With The Guidelinesâ€™ â€“ Atrial Fibrillation registry. <i>Heart Rhythm</i> , 2022, 19, 1049-1057.	0.7	1
16	Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study. <i>Cardiology and Therapy</i> , 2022, 11, 249-267.	2.6	5
17	Reducing Cardiovascular Risk in the Medicare Million Hearts Risk Reduction Model: Insights From the National Cardiovascular Data Registry PINNACLE Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, CIRCOUTCOMES121007908.	2.2	1
18	Electronic Alerts to Improve Heartâ€Failure Therapy in Outpatient Practice. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2203-2213.	2.8	86

#	ARTICLE	IF	CITATIONS
19	Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 545-556.	2.2	20
20	Thirty-Day and 90-Day Episode of Care Spending Following Heart Failure Hospitalization Among Medicare Beneficiaries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, .	2.2	3
21	Diabetes Care Among Older Adults Enrolled in Medicare Advantage Versus Traditional Medicare Fee-For-Service Plans: The Diabetes Collaborative Registry. <i>Diabetes Care</i> , 2022, 45, 1549-1557.	8.6	6
22	Assessing cardiovascular risk in cancer patients: opportunities and challenges. <i>European Journal of Preventive Cardiology</i> , 2021, 28, e45-e46.	1.8	5
23	Socio-Economic Burden of Myocardial Infarction Among Cancer Patients. <i>American Journal of Cardiology</i> , 2021, 141, 16-22.	1.6	3
24	Evaluation of Hospital Performance Using the Excess Days in Acute Care Measure in the Hospital Readmissions Reduction Program. <i>Annals of Internal Medicine</i> , 2021, 174, 86-92.	3.9	16
25	Healthcare utilization and expenditures associated with hyperkalemia management: a retrospective study of Medicare Advantage patients. <i>Journal of Medical Economics</i> , 2021, 24, 1025-1036.	2.1	5
26	Medical Student Patient Outreach to Ensure Continuity of Care During the COVID-19 Pandemic. <i>Telemedicine Reports</i> , 2021, 2, 56-63.	0.7	0
27	Effect of institutional transcatheter aortic valve replacement volume on mortality: A systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E453-E461.	1.7	5
28	Use of Mechanical Circulatory Support Devices Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. <i>JAMA Network Open</i> , 2021, 4, e2037748.	5.9	54
29	Transition From an Open to Closed Staffing Model in the Cardiac Intensive Care Unit Improves Clinical Outcomes. <i>Journal of the American Heart Association</i> , 2021, 10, e018182.	3.7	17
30	Physician variation in the deã€ adoption of ineffective statin and fibrate therapy. <i>Health Services Research</i> , 2021, 56, 919-931.	2.0	6
31	Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007759.	3.9	3
32	Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0243291.	2.5	31
33	Impact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies. <i>PLoS ONE</i> , 2021, 16, e0247789.	2.5	11
34	The impact of heart failure on patients and caregivers: A qualitative study. <i>PLoS ONE</i> , 2021, 16, e0248240.	2.5	26
35	Lowã€density lipoprotein cholesterol lowering in realã€world patients treated with evolocumab. <i>Clinical Cardiology</i> , 2021, 44, 715-722.	1.8	5
36	Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 447-455.	2.4	7

#	ARTICLE	IF	CITATIONS
37	Cardiovascular Toxicities of Androgen Deprivation Therapy. Current Treatment Options in Oncology, 2021, 22, 47.	3.0	20
38	Patterns of Care for Atrial Fibrillation Before, During, and at Discharge From Hospitalization. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009003.	4.8	2
39	Association between Respiratory Failure and Clinical Outcomes in Patients with Acute Heart Failure: Analysis of 5 Pooled Clinical Trials. Journal of Cardiac Failure, 2021, 27, 602-606.	1.7	13
40	Prevention of atherosclerotic cardiovascular disease in South Asians in the US: A clinical perspective from the National Lipid Association. Journal of Clinical Lipidology, 2021, 15, 402-422.	1.5	20
41	Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry). American Journal of Cardiology, 2021, 146, 99-106.	1.6	25
42	Outcomes in patients with anthracycline-induced cardiomyopathy undergoing left ventricular assist devices implantation. ESC Heart Failure, 2021, 8, 2866-2875.	3.1	7
43	National Trends in the Burden of Atrial Fibrillation During Hospital Admissions for Heart Failure. Journal of the American Heart Association, 2021, 10, e019412.	3.7	14
44	Use of Machine Learning Models to Predict Death After Acute Myocardial Infarction. JAMA Cardiology, 2021, 6, 633.	6.1	116
45	Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy. JACC: Heart Failure, 2021, 9, 420-429.	4.1	64
46	Comparison of Transcatheter and Open Mitral Valve Repair Among Patients With Mitral Regurgitation. Mayo Clinic Proceedings, 2021, 96, 1522-1529.	3.0	1
47	Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States. JACC: CardioOncology, 2021, 3, 236-246.	4.0	21
48	The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. Journal of Cardiac Failure, 2021, 27, 1359-1366.	1.7	2
49	REVeAL-HF. JACC: Heart Failure, 2021, 9, 409-419.	4.1	14
50	Association of obesity with venous thromboembolism and myocardial injury in COVID-19. Obesity Research and Clinical Practice, 2021, 15, 512-514.	1.8	7
51	Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure. JACC: Heart Failure, 2021, 9, 497-505.	4.1	5
52	Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2021, 10, e021084.	3.7	35
53	Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapy (RE-LY) trial. PLoS ONE, 2021, 16, e0256338.	2.5	2
54	Electronic health record risk score provides earlier prognostication of clinical outcomes in patients admitted to the cardiac intensive care unit. American Heart Journal, 2021, 238, 85-88.	2.7	5

#	ARTICLE	IF	CITATIONS
55	Mechanical ventilation at the time of heart transplantation and associations with clinical outcomes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 843-851.	1.0	8
56	Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial. <i>BMC Nephrology</i> , 2021, 22, 284.	1.8	0
57	Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes. <i>JACC: Heart Failure</i> , 2021, 9, 568-577.	4.1	8
58	Brief report: Cannabis and opioid use disorder among heart failure admissions, 2008–2018. <i>PLoS ONE</i> , 2021, 16, e0255514.	2.5	3
59	Longitudinal Outcomes Associated With Non-Evidence-Based Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries (From the National Cardiovascular Data Registry). <i>American Journal of Cardiology</i> , 2021, 155, 64-71.	1.6	1
60	Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). <i>Journal of Urology</i> , 2021, 206, 613-622.	0.4	18
61	Cannabis use disorder among atrial fibrillation admissions, 2008–2018. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 1934-1938.	1.2	2
62	Physician Network Connections Associated With Faster De-Adoption of Dronedarone for Permanent Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008040.	2.2	0
63	Forgone Medical Care Associated With Increased Health Care Costs Among the U.S. Heart Failure Population. <i>JACC: Heart Failure</i> , 2021, 9, 710-719.	4.1	14
64	Obesity and the Bidirectional Risk of Cancer and Cardiovascular Diseases in African Americans: Disparity vs. Ancestry. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 761488.	2.4	6
65	Association Between Hospital Performance Metrics and Market Share. <i>JAMA Network Open</i> , 2021, 4, e2130353.	5.9	1
66	Trends in ICD Implantations and In-Hospital Outcomes after DOJ Investigation. <i>Journal of Cardiac Failure</i> , 2021, , .	1.7	0
67	Serum Potassium and Mortality in High-Risk Patients: SPRINT. <i>Hypertension</i> , 2021, 78, 1586-1594.	2.7	3
68	Trends and Outcomes of Cardiac Transplantation in the Lowest Urgency Candidates. <i>Journal of the American Heart Association</i> , 2021, 10, e023662.	3.7	5
69	Impact of Obesity on Heart Transplantation Outcomes. <i>Journal of the American Heart Association</i> , 2021, 10, e021346.	3.7	10
70	Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. <i>Open Heart</i> , 2021, 8, e001849.	2.3	8
71	Managing the economic challenges in the treatment of heart failure. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 612.	1.7	4
72	Machine Learning Prediction of Mortality and Hospitalization in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 12-21.	4.1	152

#	ARTICLE	IF	CITATIONS
73	Financial barriers in accessing medical care for peripheral artery disease are associated with delay of presentation and adverse health status outcomes in the United States. <i>Vascular Medicine</i> , 2020, 25, 13-24.	1.5	12
74	Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 185-187.	4.1	1
75	Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization. <i>PLoS ONE</i> , 2020, 15, e0226844.	2.5	14
76	Relationship Between Provider Experience and Cardiac Performance Measures in Outpatients (from) <i>TJ ETQq0 0 0 rgrBT /Overlock 10 Tf 5</i>	2.6	0
77	Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006515.	2.2	20
78	Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation. <i>American Journal of Cardiology</i> , 2020, 133, 116-125.	1.6	13
79	Use and outcomes of wearable cardioverter-defibrillators in a large integrated academic health system. <i>American Heart Journal</i> , 2020, 226, 232-234.	2.7	0
80	Transition to Advanced Therapies in Elderly Patients Supported by Extracorporeal Membrane Oxygenation Therapy. <i>Journal of Cardiac Failure</i> , 2020, 26, 1086-1089.	1.7	11
81	Outpatient Cost-effectiveness Study of Hyperkalemia Management. <i>Journal of Cardiac Failure</i> , 2020, 26, S115.	1.7	1
82	Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump for Cardiogenic Shockâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 303.	7.4	8
83	Readmission after inferior vena cava filter placement for acute venous thromboembolism in the United States: Impact of a cancer diagnosis. <i>Journal of Cardiac Surgery</i> , 2020, 35, 2275-2278.	0.7	0
84	Quadruple Therapy Is the New Standard of Care for HFrEF. <i>JACC: Heart Failure</i> , 2020, 8, 819-821.	4.1	13
85	Association Between Industry Payments to Physicians and Device Selection in ICD Implantation. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1755.	7.4	26
86	Procedural Patterns and Safety of Atrial Fibrillation Ablation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007944.	4.8	42
87	US False Claims Act Investigations of Unnecessary Percutaneous Coronary Interventions. <i>JAMA Internal Medicine</i> , 2020, 180, 1534.	5.1	6
88	Revascularization Practices and Outcomes in Patients With Multivessel Coronary Artery Disease Who Presented With Acute Myocardial Infarction and Cardiogenic Shock in the US, 2009-2018. <i>JAMA Internal Medicine</i> , 2020, 180, 1317.	5.1	21
89	Geographical affiliation with top 10 NIH-funded academic medical centers and differences between mortality from cardiovascular disease and cancer. <i>American Heart Journal</i> , 2020, 230, 54-58.	2.7	1
90	Sex Differences in Patients Receiving Left Ventricular Assist Devices for End-Stage Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 770-779.	4.1	36

#	ARTICLE	IF	CITATIONS
91	Patient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harm. <i>International Journal of Health Economics and Management</i> , 2020, 20, 299-317.	1.1	4
92	Relative Costs of Surgical and Transcatheter Aortic Valve Replacement and Medical Therapy. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008681.	3.9	22
93	Switching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the NCDR PINNACLE registry. <i>Clinical Cardiology</i> , 2020, 43, 743-751.	1.8	15
94	Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort. <i>Journal of Clinical Lipidology</i> , 2020, 14, 695-706.e4.	1.5	15
95	Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 734.	7.4	260
96	Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data. <i>Journal of the American Heart Association</i> , 2020, 9, e013606.	3.7	10
97	Adoption of sacubitril-valsartan in the Medicare population. <i>American Heart Journal</i> , 2020, 223, 81-83.	2.7	1
98	The effect of catheter-directed thrombolytic use on readmission rates and in-hospital outcomes among cancer patients with venous thromboembolism in the United States. <i>Journal of Cardiac Surgery</i> , 2020, 35, 609-611.	0.7	1
99	Patient and hospital characteristics associated with ticagrelor uptake in acute MI: An analysis of the Chest Pain-MI Registry. <i>International Journal of Cardiology</i> , 2020, 304, 14-20.	1.7	4
100	A Novel Treatment for a Rare Cause of Cardiogenic Shock. <i>JACC: Case Reports</i> , 2020, 2, 1461-1465.	0.6	5
101	Impact of left ventricular assist devices and heart transplants on acute myocardial infarction and heart failure mortality and readmission measures. <i>PLoS ONE</i> , 2020, 15, e0230734.	2.5	1
102	Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 908-918.	2.7	13
103	COVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system. <i>PLoS ONE</i> , 2020, 15, e0238829.	2.5	21
104	Cardio-obstetrics: Recognizing and managing cardiovascular complications of pregnancy. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 43-52.	1.3	10
105	From Reactivity to Proactivity. <i>JACC: Heart Failure</i> , 2020, 8, 1035-1037.	4.1	0
106	Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure. <i>PLoS ONE</i> , 2020, 15, e0242928.	2.5	9
107	Title is missing!. , 2020, 15, e0230734.		0
108	Title is missing!. , 2020, 15, e0230734.		0

#	ARTICLE	IF	CITATIONS
109	Title is missing!. , 2020, 15, e0230734.		0
110	Title is missing!. , 2020, 15, e0230734.		0
111	Title is missing!. , 2020, 15, e0230734.		0
112	Title is missing!. , 2020, 15, e0230734.		0
113	Title is missing!. , 2020, 15, e0238829.		0
114	Title is missing!. , 2020, 15, e0238829.		0
115	Title is missing!. , 2020, 15, e0238829.		0
116	Title is missing!. , 2020, 15, e0238829.		0
117	Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. European Journal of Heart Failure, 2019, 21, 1064-1078.	7.1	79
118	Development and Testing of Improved Models to Predict Payment Using Centers for Medicare & Medicaid Services Claims Data. JAMA Network Open, 2019, 2, e198406.	5.9	3
119	National Trends in Healthcare-Associated Infections for Five Common Cardiovascular Conditions. American Journal of Cardiology, 2019, 124, 1140-1148.	1.6	17
120	Comparison of Machine Learning Methods With National Cardiovascular Data Registry Models for Prediction of Risk of Bleeding After Percutaneous Coronary Intervention. JAMA Network Open, 2019, 2, e196835.	5.9	60
121	The Reply. American Journal of Medicine, 2019, 132, e723.	1.5	0
122	National Trends in Incidence and Outcomes of Patients With Heart Failure Requiring Respiratory Support. American Journal of Cardiology, 2019, 124, 1712-1719.	1.6	13
123	Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. JAMA Network Open, 2019, 2, e1913553.	5.9	7
124	Association of Hospital Payment Profiles With Variation in 30-Day Medicare Cost for Inpatients With Heart Failure or Pneumonia. JAMA Network Open, 2019, 2, e1915604.	5.9	8
125	Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT). American Journal of Cardiology, 2019, 123, 1193-1201.	1.6	7
126	Distribution of Industry Payments Among Medical Directors of Catheterization and Electrophysiology Laboratories From the Top 100 US Hospitals. JAMA Internal Medicine, 2019, 179, 1282.	5.1	9

#	ARTICLE	IF	CITATIONS
127	The Evolving Management of Aortic Valve Disease: 5-Year Trends in SAVR, TAVR, and Medical Therapy. American Journal of Cardiology, 2019, 124, 763-771.	1.6	42
128	The Quality Chasm Between Administrative Coding and Accurate Phenotyping of Heart Failure. Journal of Cardiac Failure, 2019, 25, 490-492.	1.7	2
129	Digoxin Use and Associated Adverse Events Among Older Adults. American Journal of Medicine, 2019, 132, 1191-1198.	1.5	23
130	Association of in-hospital resource utilization with post-acute spending in Medicare beneficiaries hospitalized for acute myocardial infarction: a cross-sectional study. BMC Health Services Research, 2019, 19, 190.	2.2	3
131	Association of access to exercise opportunities and cardiovascular mortality. American Heart Journal, 2019, 212, 152-156.	2.7	5
132	Trends in Performance and Opportunities for Improvement on a Composite Measure of Acute Myocardial Infarction Care. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004983.	2.2	19
133	Predictive Abilities of Machine Learning Techniques May Be Limited by Dataset Characteristics: Insights From the UNOS Database. Journal of Cardiac Failure, 2019, 25, 479-483.	1.7	48
134	Financial Hardship From Medical Bills Among Nonelderly U.S. Adults With Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology, 2019, 73, 727-732.	2.8	56
135	Relationship Between Patient-Reported Hospital Experience and 30-Day Mortality and Readmission Rates for Acute Myocardial Infarction, Heart Failure, and Pneumonia. Journal of General Internal Medicine, 2019, 34, 526-528.	2.6	8
136	<p>Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified<p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 1325-1332.	2.0	4
137	Clinical Implications of Respiratory Failure in Patients Receiving Durable Left Ventricular Assist Devices for End-Stage Heart Failure. Circulation: Heart Failure, 2019, 12, e006369.	3.9	13
138	Coronary artery bypass grafting surgery versus percutaneous coronary intervention for coronary artery disease. The Cochrane Library, 2019, , .	2.8	0
139	Clinical Outcomes After Left Ventricular Assist Device Implantation in Older Adults. JACC: Heart Failure, 2019, 7, 1069-1078.	4.1	25
140	Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes. Journal of the American Heart Association, 2019, 8, e010373.	3.7	8
141	Strength of Evidence Underlying the American Heart Association/American College of Cardiology Guidelines on Endovascular and Surgical Treatment of Peripheral Vascular Disease:. Circulation: Cardiovascular Interventions, 2019, 12, e007244.	3.9	16
142	Variation in the Use of Warfarin and Direct Oral Anticoagulants in Atrial Fibrillation and Associated Cost Implications. American Journal of Medicine, 2019, 132, 61-70.e1.	1.5	22
143	The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population. American Health and Drug Benefits, 2019, 12, 352-361.	0.5	3
144	Hospital Characteristics Associated With Postdischarge Hospital Readmission, Observation, and Emergency Department Utilization. Medical Care, 2018, 56, 281-289.	2.4	20

#	ARTICLE	IF	CITATIONS
145	Persistent socioeconomic disparities in cardiovascular risk factors and health in the United States: Medical Expenditure Panel Survey 2002–2013. <i>Atherosclerosis</i> , 2018, 269, 301-305.	0.8	27
146	Variation in practice patterns and outcomes across United Network for Organ Sharing allocation regions. <i>Clinical Cardiology</i> , 2018, 41, 81-86.	1.8	3
147	Favorable Modifiable Cardiovascular Risk Profile Is Associated With Lower Healthcare Costs Among Cancer Patients: The 2012–2013 Medical Expenditure Panel Survey. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	11
148	Essential Elements of Early Post Discharge Care of Patients with Heart Failure. <i>Current Heart Failure Reports</i> , 2018, 15, 181-190.	3.3	7
149	The Twittersphere Needs Academic Cardiologists!. <i>JACC: Heart Failure</i> , 2018, 6, 172-173.	4.1	11
150	Industry Payments to Cardiologists. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e005016.	2.2	28
151	Alirocumab's Price Reduction. <i>Circulation</i> , 2018, 138, 1502-1504.	1.6	5
152	Trends in 30-Day Readmission Rates for Medicare and Non-Medicare Patients in the Era of the Affordable Care Act. <i>American Journal of Medicine</i> , 2018, 131, 1324-1331.e14.	1.5	28
153	Managing the Economic Challenges in the Treatment of Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2018, 61, 476-483.	3.1	4
154	Variation in and Hospital Characteristics Associated With the Value of Care for Medicare Beneficiaries With Acute Myocardial Infarction, Heart Failure, and Pneumonia. <i>JAMA Network Open</i> , 2018, 1, e183519.	5.9	9
155	National Landscape of Unplanned 30-Day Readmissions in Patients With Left Ventricular Assist Device Implantation. <i>American Journal of Cardiology</i> , 2018, 122, 261-267.	1.6	12
156	Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004054.	2.2	30
157	Association of the US Department of Justice Investigation of Implantable Cardioverter-Defibrillators and Devices Not Meeting the Medicare National Coverage Determination, 2007-2015. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 63.	7.4	14
158	Sex and Race Differences in the Utilization and Outcomes of Coronary Artery Bypass Grafting Among Medicare Beneficiaries, 1999–2014. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	40
159	Early Experiences With Journal Data Sharing Policies: A Survey of Published Clinical Trial Investigators. <i>Annals of Internal Medicine</i> , 2018, 169, 586.	3.9	12
160	Age of Data at the Time of Publication of Contemporary Clinical Trials. <i>JAMA Network Open</i> , 2018, 1, e181065.	5.9	23
161	National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	21
162	Overview and experience of the YODA Project with clinical trial data sharing after 5 years. <i>Scientific Data</i> , 2018, 5, 180268.	5.3	48

#	ARTICLE	IF	CITATIONS
163	Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 232-243.	1.0	9
164	National Trends in Atrial Fibrillation Hospitalization, Readmission, and Mortality for Medicare Beneficiaries, 1999-2013. <i>Circulation</i> , 2017, 135, 1227-1239.	1.6	110
165	Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. <i>JAMA Cardiology</i> , 2017, 2, 556.	6.1	22
166	PCI Appropriateness in New York. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1243-1246.	2.8	7
167	Trends in Cardiovascular Health of US Adults by Income, 2005-2014. <i>JAMA Cardiology</i> , 2017, 2, 814.	6.1	28
168	National Trends in Use and Outcomes of Pulmonary Artery Catheters Among Medicare Beneficiaries, 1999-2013. <i>JAMA Cardiology</i> , 2017, 2, 908.	6.1	54
169	Contemporary risk model for in-hospital major bleeding for patients with acute myocardial infarction: The acute coronary treatment and intervention outcomes network (ACTION) registry-Get With The Guidelines (CWTC). <i>American Heart Journal</i> , 2017, 194, 16-24.	2.7	28
170	A Blueprint for the Post Discharge Clinic Visit after an Admission for Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2017, 60, 237-248.	3.1	11
171	Inferior Vena Cava Filters to Prevent Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1587-1597.	2.8	134
172	Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital Discharge. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 270.	7.4	176
173	Data Sharing and Cardiology. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3018-3025.	2.8	11
174	The Impact of the Transition From Volume to Value on Heart Failure Care: Implications of Novel Payment Models and Quality Improvement Initiatives. <i>Journal of Cardiac Failure</i> , 2017, 23, 615-620.	1.7	22
175	National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013. <i>JAMA Cardiology</i> , 2017, 2, 56.	6.1	297
176	Outcomes after observation stays among older adult Medicare beneficiaries in the USA: retrospective cohort study. <i>BMJ: British Medical Journal</i> , 2017, 357, j2616.	2.3	18
177	Are non-ST-segment elevation myocardial infarctions missing in China?. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2017, 3, 319-327.	4.0	13
178	Can machine learning complement traditional medical device surveillance? A case-study of dual-chamber implantable cardioverter–defibrillators. <i>Medical Devices: Evidence and Research</i> , 2017, Volume 10, 165-188.	0.8	9
179	Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. <i>Trials</i> , 2017, 18, 333.	1.6	43
180	National Assessment of Statin Therapy in Patients Hospitalized with Acute Myocardial Infarction: Insight from China PEACE-Retrospective AMI Study, 2001, 2006, 2011. <i>PLoS ONE</i> , 2016, 11, e0150806.	2.5	10

#	ARTICLE	IF	CITATIONS
181	Trajectories of Risk for Specific Readmission Diagnoses after Hospitalization for Heart Failure, Acute Myocardial Infarction, or Pneumonia. PLoS ONE, 2016, 11, e0160492.	2.5	39
182	Practice-Level Variation in Outpatient Cardiac Care and Association With Outcomes. Journal of the American Heart Association, 2016, 5, .	3.7	7
183	Data sharing through an NIH central database repository: a cross-sectional survey of BioLINCC users. BMJ Open, 2016, 6, e012769.	1.9	24
184	Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions. JAMA - Journal of the American Medical Association, 2016, 316, 2647.	7.4	230
185	Toward evidence-based health care delivery reform. American Heart Journal, 2016, 174, 154-156.	2.7	0
186	Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	3.7	100
187	Geographic Variation in Trends and Disparities in Acute Myocardial Infarction Hospitalization and Mortality by Income Levels, 1999-2013. JAMA Cardiology, 2016, 1, 255.	6.1	64
188	Assessing Hospital Performance for Emerging Technologies. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 498-500.	2.2	3
189	Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ, The, 2016, 352, i637.	6.0	165
190	Availability of Clinical Trial Data From Industry-Sponsored Cardiovascular Trials. Journal of the American Heart Association, 2016, 5, e003307.	3.7	15
191	Trends in Short- and Long-Term Outcomes for Takotsubo Cardiomyopathy Among Medicare Fee-for-Service Beneficiaries, 2007 to 2012. JACC: Heart Failure, 2016, 4, 197-205.	4.1	64
192	Vena Caval Filter Utilization and Outcomes in Pulmonary Embolism. Journal of the American College of Cardiology, 2016, 67, 1027-1035.	2.8	61
193	Clinical Implications of Cluster Analysis-Based Classification of Acute Decompensated Heart Failure and Correlation with Bedside Hemodynamic Profiles. PLoS ONE, 2016, 11, e0145881.	2.5	30
194	Insurance and Prehospital Delay in Patients ≥ 55 Years With Acute Myocardial Infarction. American Journal of Cardiology, 2015, 116, 1827-1832.	1.6	10
195	Reporting of Noninferiority Trials in ClinicalTrials.gov and Corresponding Publications. JAMA - Journal of the American Medical Association, 2015, 313, 1163.	7.4	20
196	National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE)-Retrospective AMI Study, 2001, 2006, and 2011. Journal of the American Heart Association, 2015, 4, e001718.	3.7	7
197	National Quality Assessment of Early Clopidogrel Therapy in Chinese Patients With Acute Myocardial Infarction (AMI) in 2006 and 2011: Insights From the China Patient-centered Evaluative Assessment of Cardiac Events (PEACE)-Retrospective AMI Study. Journal of the American Heart Association, 2015, 4, .	3.7	15
198	National assessment of early β -blocker therapy in patients with acute myocardial infarction in China, 2001-2011: The China Patient-centered Evaluative Assessment of Cardiac Events (PEACE)-Retrospective AMI Study. American Heart Journal, 2015, 170, 506-515.e1.	2.7	13

#	ARTICLE	IF	CITATIONS
199	PCSK9 inhibition in patients with hypercholesterolemia. Trends in Cardiovascular Medicine, 2015, 25, 567-574.	4.9	24
200	National Institutes of Health Career Development Awards for Cardiovascular“Physician”Scientists. Journal of the American College of Cardiology, 2015, 66, 1816-1827.	2.8	12
201	Obstacles to Developing Cost-Lowering Health Technology. JAMA - Journal of the American Medical Association, 2015, 314, 1447.	7.4	5
202	Patterns of Institutional Review of Percutaneous Coronary Intervention Appropriateness and the Effect on Quality of Care and Clinical Outcomes. JAMA Internal Medicine, 2015, 175, 1988.	5.1	2
203	Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2015, 314, 2045.	7.4	212
204	Trends in Cardiac Biomarker Testing in China for Patients with Acute Myocardial Infarction, 2001 to 2011: China PEACE-Retrospective AMI Study. PLoS ONE, 2015, 10, e0122237.	2.5	8
205	National Trends in Hospital Readmission Rates among Medicare Fee-for-Service Survivors of Mitral Valve Surgery, 1999”2010. PLoS ONE, 2015, 10, e0132470.	2.5	12
206	Trends in Early Aspirin Use Among Patients With Acute Myocardial Infarction in China, 2001”2011: The China PEACE”Retrospective AMI Study. Journal of the American Heart Association, 2014, 3, e001250.	3.7	13
207	Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease. Journal of the American College of Cardiology, 2014, 63, 520-527.	2.8	152
208	Patterns of Initiation of Oral Anticoagulants in”Patients with Atrial Fibrillation” Quality and Cost Implications. American Journal of Medicine, 2014, 127, 1075-1082.e1.	1.5	199
209	Impact of <i>CYP2C19</i> Genetic Testing on Provider Prescribing Patterns for Antiplatelet Therapy After Acute Coronary Syndromes and Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 694-699.	2.2	14